Skip to content
Open Treatments Foundation

Enabling treatments for rare diseases

OpenTreatments software platform streamlines therapy development for any monogenic rare disease regardless of rarity and geography

Explore Our Platform

Empowered to take action

When it comes to finding treatments for rare diseases patients lead the charge. Without a formal background, they must learn biology, speak like a scientist, raise millions of dollars, conduct research, and move mountains to find a treatment. They are often asked to make life-altering decisions without much background, or support. OpenTreatments Foundation empowers these patient organizations by giving them the software tools to make the right decisions at the right time, with a system of support.

Simplify the maze

Patient organizations are left to navigate the complex treatment development maze. Each patient group creates their own research program without a deep understanding of the risks, benefits, and pitfalls of their decisions. OpenTreatments platform simplifies the maze by bringing in real-world experience along every step leading to faster treatments.

Our Collaborators

  • Baylor College of Medicine
  • Castle IRB
  • Charles River
  • Columbus Children's Foundation
  • Global Genes
  • Odylia Therapeutics
  • RARE-X
  • Turing
A treatment roadmap in the OpenTreatments platform

OpenTreatments Platform

A software platform to give patients the tools and technology to build treatments for any monogenic rare disease

Learn more

Try OpenTreatments Platform

We are currently piloting OpenTreatments platform with 4 patient led organizations

  • CureGPX4
  • IDefine
  • CureCMD
  • INADcure

Join the waitlist to get priority access when we open more broadly.

Your name
Geoff Rhyne
“OpenTreatments will enable IDefine to accelerate our mission by distilling down the necessary steps in the development of a gene therapy program into a concise and approachable plan”

— Geoff Rhyne, Co-Founder and CEO of IDefine, a patient-led organization tackling Kleefstra Syndrome caused by mutations in EHMT1 gene.